Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

IP

Intelliject has 33 patents issued and more than 60 others pending.

Our IP portfolio has been built around key constituent parts and sub-assemblies, rather than a specific finished design. This allows us to be true to our vision of designing delivery systems highly specific to the needs of a particular audience, while still protecting our intellectual property.

As an example, the very different needs of an acute rescue therapy that needs to be with the patient at all times, versus an infrequently administered chronic medicine taken in a regular routine, may mandate products with quite different size, look and feel.

Each device, however, will incorporate elements of key proprietary technologies that support improved effectiveness.

Why Now?

More than 100 US medicines' patents expired in 2009 Read More

Clinical & Cost Data

Intelliject studies generate head-to-head data versus the current Standard of Care. View our Clinical & Cost Data

Key patent expiries by 2012:

Zyprexa, Plavix, Seroquel, Lipitor Why Now?

Anaphylaxis Solution Video

To see a video demonstrating how Intelliject's product could theoretically be used in anaphylactic emergency, click here

Loss of Patent Protection

Of the 20 biggest drugs in the world, 18 will lose patent protection in the next five years. Why Now?

Hypoglycemia Solution Video

To see a video demonstrating how Intelliject's product could theoretically be used in hypoglycemic emergency, click here

Why Now?

$1.3 billion to bring a new drug to market in 2009.Read More

Solutions

Intelliject's pipeline targets a number of areas requiring self/caregiver administered injections.Read More

Why Now?

2009-2014: Injectable drug sales will increase by $42 billion. Read More

Patient-Centric

Human Factors Engineering (HFE) is central to ensuring that Intelliject's products are patient-centric Learn More

THIS WEBSITE IS NOT INTENDED FOR PATIENTS OR HEALTHCARE PROFESSIONALS. Members of the public, patients and healthcare professionals should not enter this website. If you are a patient, please see your healthcare professional for more information. This website is intended solely for entities that are current or potential business partners of Intelliject, Inc. Intelliject currently has NO FDA APPROVED PRODUCTS and nothing herein is a promotional therapeutic claim.

All information contained herein is intended to assist interested parties in assessing possible business relationships with Intelliject, Inc. All information is believed to be correct at the date of posting but may change at any time.

I have read the statements above. I am an interested party assessing possible business relationships with Intelliject, Inc.